MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal® G4 HIV-1/2 rapid test for VA, Department of Defence

Halifax, Nova Scotia, 17th of April, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira’s Service-Disabled Veteran-Owned […]
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System

Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this new patent, MedMira is to further diversify its patent portfolio […]
MedMira’s G4 HIV (FDA approved) rapid test – an independent evaluation by the CDC

Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens Rebecca Rossetti1, Tara Smith2, Wei Luo1, Silvina Masciotra1 1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention2Oak Ridge Institute for Science and Education Download the full study